Morepen Laboratories Ltd is engaged in the business of manufacturing, producing, developing and marketing a wide range of Active Pharmaceutical Ingredients (APIs),
Categories
API
NGL Fine Chem Ltd Q1FY24; 1431% rise in Profits
Established in 1981, NGL Fine-Chem Limited manufacturers and markets APIs, Intermediates and Finished Dosage forms for human and animal pharmaceutical product. It
Vaishali Pharma Ltd Q1FY24; 5% rise in Profits
Incorporated in 1989, Vaishali Pharma Ltd. is engaged in the manufacturing, trading & marketing of Active Pharmaceutical Ingredients(APIs), pharmaceuticals formulations, surgical products,
Par Drugs & Chemicals Ltd Q1FY24; 8% rise in Profits
Par Drugs & Chemicals Ltd is primarily engaged in manufacturing of Active Pharma Ingredients (APIs) and fine chemicals for domestic & international
Supriya Lifescience Ltd Q1FY24; 16% rise in Profits
Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs
Sun Pharmaceuticals Industries Ltd Q1FY24; 4% fall in Profits
Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations
RPG Life Sciences Ltd Q1FY24; 22% rise in Profits
RPG Life Sciences Ltd is engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs) in
Unichem Laboratories Ltd Q1FY24; 37% rise in Revenue
Unichem Laboratories Ltd is involved in pharmaceuticals in Generics, APIs and Contract Manufacturing (CMO) areas. Financial Results: Unichem Laboratories Ltd reported Revenues
Sun Pharmaceuticals Ltd Q4FY23 results out, revenue grows by 16%
Sun Pharmaceuticals Ltd reported Total revenue for Q4 FY23 of ₹10,931 Crore, up from ₹9,447 Crore year on year depicting a growth
Suven Pharmaceuticals Ltd Q4FY23 results out, net profit grows by 35%
Suven Pharma is in the business of Contract development & manufacturing organisation (CDMO), catering to the needs of global Pharma Industry. SPL
Divi’s Laboratories Ltd Q4 FY23 Earnings Conference Call Insights
Key highlights from Divi's Laboratories Ltd (DIVISLAB) Q4 FY23 Earnings Concall Q&A Highlights: [00:11:30] Tushar Manudhane from Motilal Oswal asked if backward
Zydus Lifescience Ltd Q4FY23 results out, revenue grows by 32%
In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble
Solara Active Pharma Q4FY23 results out, revenue grows by 6%
Solara Active Pharma Sciences Ltd is engaged in business of manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of APIs.
Tanla Platform Q4FY23 results out, revenue drops by 2%
Tanla Platforms Ltd (formerly Tanla Solutions Ltd) is a cloud communications provider enabling businesses to communicate with their customers and intended recipients.
Laurus Labs Q3FY23 net profit rises by 32 percent
Pharmaceutical and biotechnology company Laurus Labs reported 32% year-on-year (YoY) rise in profit after tax to INR 203 crore for the quarter
Wockhardt posted a net loss of INR 102 Crores in Q3FY23
Drugmaker Wockhardt posted a consolidated loss of ₹102 crore for the three months ended December 31, 2022. The company posted a profit
Lupin Q2FY23 results out: Net profit rises more than 100%
Shares of Lupin gained as much as 8 percent in early trading on Thursday after the company returned to profitability during the
Divi’s Laboratories Ltd Q2 FY23 Earnings Conference Call Insights
https://youtu.be/e1-tljnhSVM Key highlights from Divi's Laboratories Ltd (DIVISLAB) Q2 FY23 Earnings Concall Management Update: [00:06:48] DIVISLAB stated that though global logistics scenario
Decoding India’s leading API development company – Dr Reddy’s Laboratories
About Company: Founded in 1984 and headquartered in Hyderabad, India, Dr Reddy’s Laboratories (DRL) is India’s second largest pharma company by global
Divi’s Laboratories Ltd Q1 FY23 Earnings Conference Call Insights
https://youtu.be/EPaxfKgyoZQ Key highlights from Divi's Laboratories Ltd (DIVISLAB) Q1 FY23 Earnings Concall Q&A Highlights: Tushar Manudhane from Motilal Oswal asked about the
Infographic: Divi’s Lab Q1 results out, Net profit rises 26%
On Friday, Pharmaceuticals company Divis Laboratories reported a 26% rise in its consolidated net profit at ₹702 crore as compared to ₹557